InvestLog
EVMN Evommune, Inc. logo

EVMN Evommune, Inc.

Healthcare
$22.87-2.89%ClosedMarket Cap: $323.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.53

P/S

32.39

EV/EBITDA

-3.60

DCF Value

$-64.25

FCF Yield

-24.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

92.8%

Operating Margin

-899.9%

Net Margin

-759.9%

ROE

-195.2%

ROA

-23.6%

ROIC

-28.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-21.7M$—
Q4 null$0.00$-28.3M$—
FY null$13.0M$-68.9M$—
Q3 null$10.0M$-12.5M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$49.83

Target (Median)

$48.50

Target Range

$40.00 - $65.00

2 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell
Morgan StanleyOverweight
2026-05-11
RBC CapitalOutperform
2026-04-10
HC Wainwright & Co.Buy
2026-03-18
HC Wainwright & Co.Buy
2026-02-10

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.30

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Peers

ARTV logoARTVCDXS logoCDXSCLYM logoCLYMEYPT logoEYPTFTRE logoFTREGLPG logoGLPGKPTI logoKPTILGND logoLGNDOABI logoOABIZYME logoZYME